Ensysce Biosciences Files Proxy Materials
Ticker: ENSCW · Form: DEFA14A · Filed: Dec 16, 2025 · CIK: 1716947
| Field | Detail |
|---|---|
| Company | Ensysce Biosciences, INC. (ENSCW) |
| Form Type | DEFA14A |
| Filed Date | Dec 16, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-filing, corporate-governance
Related Tickers: ENSY
TL;DR
Ensysce Biosciences (ENSY) filed proxy docs, no fee. Looks like standard corporate housekeeping.
AI Summary
Ensysce Biosciences, Inc. filed a Definitive Additional Materials (DEFA14A) on December 16, 2025. This filing relates to proxy materials and does not require a fee. The company, previously known as Leisure Acquisition Corp., is incorporated in Delaware and operates in the Pharmaceutical Preparations industry.
Why It Matters
This filing indicates that Ensysce Biosciences is proceeding with corporate actions requiring shareholder approval or information, which could impact the company's future direction and shareholder rights.
Risk Assessment
Risk Level: low — This filing is a routine proxy statement, not indicating any immediate financial distress or significant new risks.
Key Players & Entities
- Ensysce Biosciences, Inc. (company) — Registrant
- Leisure Acquisition Corp. (company) — Former company name
- 20251216 (date) — Filing date
FAQ
What is the purpose of this DEFA14A filing?
This filing is for Definitive Additional Materials related to proxy statements, as per Section 14(a) of the Securities Exchange Act of 1934.
Was a fee required for this filing?
No, the filing indicates that no fee was required for this submission.
What was Ensysce Biosciences, Inc. formerly known as?
Ensysce Biosciences, Inc. was formerly known as Leisure Acquisition Corp.
When was the company name changed?
The date of the name change from Leisure Acquisition Corp. to Ensysce Biosciences, Inc. was September 13, 2017.
What is the primary business of Ensysce Biosciences, Inc.?
The company is classified under the Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
Filing Stats: 126 words · 1 min read · ~1 pages · Grade level 12.3 · Accepted 2025-12-16 16:34:45
Filing Documents
- formdefa14a.htm (DEFA14A) — 14KB
- formdefa14a_001.jpg (GRAPHIC) — 294KB
- formdefa14a_002.jpg (GRAPHIC) — 497KB
- formdefa14a_003.jpg (GRAPHIC) — 496KB
- 0001493152-25-027975.txt ( ) — 1789KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to §240.14a-12 Ensysce Biosciences, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.